Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Encompass Health Corporation’s (NYSE: EHC) SEC filings, offering detailed insight into the company’s inpatient rehabilitation hospital business and financial profile. As the largest owner and operator of inpatient rehabilitation hospitals in the United States, Encompass Health uses its filings to report operating results, liquidity measures and other material information.
Current reports on Form 8-K included in the available information show how the company discloses quarterly financial results, updates to full-year guidance and investor materials. These filings reference metrics such as net operating revenue, Adjusted EBITDA, adjusted earnings per share, leverage ratio and adjusted free cash flow, along with explanations of why non-GAAP measures are used and how they are reconciled to comparable GAAP figures.
Other 8-K filings address topics like publication of an Investor Reference Book, which provides an overview of the company and its industry, business outlook, growth strategy and operational initiatives, as well as Regulation FD communications when senior management meets with investors and analysts. Governance-related 8-Ks can also appear, such as notices of director departures.
Through this filings page, users can review Encompass Health’s earnings-related 8-Ks, Regulation FD disclosures and other material event reports as they are made available via EDGAR. AI-powered tools on the platform can help summarize lengthy documents, highlight key metrics and clarify definitions of non-GAAP measures like Adjusted EBITDA and adjusted free cash flow, making it easier to understand how the company evaluates performance, manages leverage and plans for growth.
For anyone analyzing EHC stock, these SEC filings are a primary source for understanding Encompass Health’s financial condition, risk disclosures, capital structure and strategic communications with investors.
Encompass Health Corp ownership disclosure: The Vanguard Group filed an amendment to its Schedule 13G stating it beneficially owns 0 shares of Encompass Health Corp common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries/divisions to report separately.
Encompass Health Corporation entered a new credit agreement on March 9, 2026, establishing a $1 billion revolving credit facility with a maturity of March 9, 2031. The facility includes a $260 million letter of credit subfacility and a swingline loan sublimit increased to $40 million.
The company used $250.0 million of borrowings and $53.6 million of letters of credit under the new facility to repay and retire all remaining obligations under its prior 2022 credit agreement, which was terminated along with its related collateral and guarantee agreement.
The new agreement keeps terms substantially similar but lowers the undrawn commitment fee by 5 basis points, eliminates a 0.10% Term SOFR interest adjustment, relaxes certain investment, debt, lien, and restricted payment limits, and adds an accordion feature allowing additional term loans or increased revolving commitments, subject to leverage and coverage covenants.
Encompass Health Corp senior vice president and treasurer Edmund Fay reported an open-market sale and a charitable gift of company stock. On March 9, 2026, he sold 11,937 shares of Encompass Health common stock at $107 per share, then donated 3,000 shares as a bona fide gift to a donor advised fund administered by Schwab. After these transactions, Fay directly holds 86,325 shares of Encompass Health common stock, indicating he retains a substantial equity stake in the company.
Encompass Health Corp Chief Accounting Officer handles tax withholding via share disposition
Encompass Health Corp executive Andrew L. Price reported a tax-withholding disposition of 307 shares of Encompass Health common stock on this Form 4. The shares, valued at $107.88 each, were withheld or surrendered to cover tax obligations from vesting restricted stock, not sold in an open‑market trade.
After this transaction, Price directly holds 74,694 shares of Encompass Health common stock.
Encompass Health Corp senior vice president and treasurer Edmund Fay reported a small share disposition related to tax withholding. On the transaction date, 280 shares of Encompass Health common stock were withheld at $107.88 per share to cover tax obligations from vesting restricted stock. After this tax-withholding disposition, Fay directly owned 101,262 shares of Encompass Health common stock.
Encompass Health Corp Chief Medical Officer Elissa Joy Charbonneau had 369 shares of Encompass Health common stock withheld at a price of $107.88 per share to cover tax obligations from vesting restricted stock. After this tax-withholding disposition, she directly holds 17,644.061 shares.
Encompass Health Corp executive John Patrick Darby reported routine equity compensation activity. He received a grant of 5,967 non-qualified stock options at $108.06 per share, which become exercisable in equal installments over three years starting March 2, 2027. Separately, 416 shares of common stock were disposed of to satisfy tax withholding obligations tied to the vesting of related restricted stock, rather than through an open-market sale.
Encompass Health Corp President & CEO Mark J. Tarr reported a mix of equity award activity and tax-related share withholding. He received a grant of non-qualified stock options covering 35,461 shares at an exercise price of $108.06 per share. According to the disclosure, these options become exercisable in equal annual installments over a three-year period beginning March 2, 2027.
In a separate transaction, 2,187 shares of Encompass Health common stock were withheld or surrendered at $107.88 per share to satisfy tax withholding obligations tied to the vesting of related restricted stock. After these transactions, Tarr directly held 440,962 shares of common stock.
Encompass Health Corp executive Patrick William Tuer reported two equity-related transactions. He received a grant of 10,502 non-qualified stock options at an exercise price of $108.06 per share, which become exercisable in three equal annual installments starting on March 2, 2027. Separately, 545 shares of common stock at $107.88 per share were withheld to cover tax obligations arising from the vesting of related restricted stock, leaving him with 25,437 directly held shares.
Encompass Health Corp executive Douglas E. Coltharp reported a new stock option grant and a related tax-withholding share disposition. He received a non-qualified stock option for 12,275 shares at $108.06 per share, which becomes exercisable in equal annual installments over three years starting March 2, 2027.
To cover tax obligations from restricted stock vesting, 776 common shares were withheld at $107.88 per share, leaving him with 69,377 directly owned common shares. The filing also lists indirect holdings held through irrevocable trusts and by his spouse, totaling additional baseline share positions.